DCM
TTPH

Delpha Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Delpha Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-117
Closed -$15K – 1518
2017
Q4 		$15K Buy
+117
New +$15K 0.02% 911

Other funds holding TTPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Delpha Capital Management's TTPH Position: Q1 2018 in Review

Delpha Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 117 shares — an estimated $15K sold.

Delpha Capital Management first reported a position in TTPH in Q4 2017 and held it in 1 quarter. The position peaked at $15K in Q4 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

  • Delpha Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 117 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $15K.
  • Delpha Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $15K in Q4 2017.
  • 94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.